Trexquant Investment’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Trexquant Investment’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-16,145	Closed	-$613K	–	1873
2022 Q4	$613K	Buy	+16,145	New	+$556K	0.02%	830
2021 Q2	–	Sell	-2,060	Closed	-$205K	–	1610
2021 Q1	$205K	Buy	2,060 +11	+0.5%	+$1.28K	0.02%	957
2020 Q4	$253K	Buy	+2,049	New	+$269K	0.03%	786
2019 Q4	–	Sell	-3,267	Closed	-$262K	–	1326
2019 Q3	$262K	Buy	+3,267	New	+$277K	0.02%	663
2019 Q2	–	Sell	-6,682	Closed	-$571K	–	1212
2019 Q1	$571K	Sell	6,682 -4,681	-41%	-$389K	0.04%	552
2018 Q4	$637K	Buy	+11,363	New	+$694K	0.04%	555

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trexquant Investment's RETA Position: Q1 2023 in Review

Trexquant Investment sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 16,145 shares — an estimated $613K sold.

Trexquant Investment first reported a position in RETA in Q4 2018 and held it in 6 quarters. The position peaked at $637K in Q4 2018. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Trexquant Investment reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Trexquant Investment sold 16,145 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $613K.
Trexquant Investment first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and held it in 6 quarters.
Trexquant Investment's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $637K in Q4 2018.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Trexquant Investment's 13F filing for Q1 2023, filed 15 May 2023.